Pharmacia Laboratories, Inc. v. United States
This text of 609 F.2d 491 (Pharmacia Laboratories, Inc. v. United States) is published on Counsel Stack Legal Research, covering Court of Customs and Patent Appeals primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
Opinion
Pharmacia appeals from a judgment of the U.S. Customs Court, 82 Cust. Ct. 166, C.D. 4798, 470 F. Supp. 853 (1979), affirming the Government’s classification of certain radioimmunoassay diagnostic test kits under item 799.00,2 TSUS, rather than item 494.50,3 TSUS. We affirm.
[6]*6Background
The kits, used to detect certain chemicals in blood serum, consist of four or five separate vials, one containing a radioactive substance and the others containing ingredients needed to conduct the test. Pharmacia protested classification under 799.00, but conceded that if classification as usefully radioactive chemical compounds under item 494.50 was not proper, the kits would be properly classified under item 799.00.
Customs Court
The parties agreed that the kits were entireties for purposes of customs classification. Judge James L. Watson, held classification proper under TSUS item 799.00 of any of three grounds: (1) The kits are not chemical compounds within the meaning of “compound” in headnote 2 of schedule 44 and thus do not come within the plain meaning of the claimed provision; (2) each kit consists of a number of vials containing separate and distinct compounds, and is thus too diverse to be properly described by the claimed provision; and (3) the nonradioactive compounds being as important to the results of the test as the radioactive compound, the latter should not determine classification of the kit.
Issue
The sole question presented is whether the imported kits are classifiable as “usefully radioactive compounds.” 5
OPINION
Pharmacia argues that because the kits in issue are bought, sold, stored, used, and discharged as though they were radioactive compounds, they should be classified as such.
[7]*7The United States argues that because (1) the kits have several components, only one being radioactive, (2) the function of the kits requires nonradioactive components, and (3) the kit does not meet the definition of “compound” in the TSUS, the kits are not classifiable under item 494.50.
Arguments (1) and (2) of the United States are but different statements of its position that the imported kits are “other than” or “more than” usefully radioactive compounds.
“[I]t is well settled that articles which in fact constitute more than other articles are not classifiable under provisions applicable to those other articles.” Pollard Bearings Corp. v. United States, 62 CCPA 61, 64, C.A.D. 1146, 511 F. 2d 568, 571 (1975) (quoting United States v. Flex Track Equipment Ltd., 59 CCPA 97, C.A.D. 1046, 458 F. 2d 148 (1972)).
Pharmacia’s expert witness testified that the kit contains two components necessary to conduct the test, the radioactive element and the antibody. He admitted that the antibody determines the character of the test, and that the test cannot measure anything without the antibody.
Judge Watson found from the testimony and exhibits that two components, the antibody and the standard, were at least as important to the test as the radioactive element. This court will not reverse on questions of fact unless the findings are clearly contrary to the weight of the evidence. Pollard Bearings, supra, United States v. F. W. Myers & Co., 45 CCPA 48, 52, C.A.D. 671 (1958). Far from any question of contrariness to the weight of the evidence here, Judge Watson’s finding that other components are as important as the radioactive component is amply supported by the record. In view of the importance of its other components, it is apparent that the kit is more than a radioactive compound.
Argument (3) of the United States is also correct. The imported kit, consisting of a number of vials, does not meet the definition of “compound” in schedule 4, headnote 2(a). It is not a “substance occurring naturally or produced artificially by the. reaction of two or more ingredients.”
Hence, classification of the imported kits under 494.50 would be improper whether they be viewed as more than “usefully radioactive compounds” or as failing to meet the definition of “compound.”
Treatment of the kit as a radioactive compound is of no moment here. Rules and regulations governing storage, handling, and use of radioactive materials were developed to protect the public safety, not as guidance to customs classification.
The judgment of the Customs Court is affirmed.
Free access — add to your briefcase to read the full text and ask questions with AI
Related
Cite This Page — Counsel Stack
609 F.2d 491, 67 C.C.P.A. 5, 1979 CCPA LEXIS 190, Counsel Stack Legal Research, https://law.counselstack.com/opinion/pharmacia-laboratories-inc-v-united-states-ccpa-1979.